Skip to main content

Advertisement

SpringerLink
Log in

Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients

  • Letter to the Editor
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390–7.

    Article  PubMed  Google Scholar 

  2. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–41.

    Article  PubMed  Google Scholar 

  3. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–86.

    Article  PubMed  Google Scholar 

  4. von Bahr L, Sundberg B, Lönnies L, Sander B, Karbach H, Hägglund H, Ljungman P, Gustafsson B, Karlsson H, Le Blanc K, Ringdén O. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant. 2012;18(4):557–64.

    Article  Google Scholar 

  5. von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. BMT. 2009;43:245–51.

    Google Scholar 

  6. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57(1):11–20.

    Article  PubMed  Google Scholar 

  7. Blennow O, Remberger M, Klingspor L, Omazic B, Fransson K, Ljungman P, et al. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant. 2010;45:1710–8.

    Article  PubMed  CAS  Google Scholar 

  8. Tollemar J, Ringdén O, Boström L, Nilsson B, Sundberg B. Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 1989;4(6):635–41.

    PubMed  CAS  Google Scholar 

  9. LeBlanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007;262(5):509–25.

    Article  CAS  Google Scholar 

  10. Spaggiari GM, Moretta L. Interactions between mesenchymal stem cells and dendritic cells. Adv Biochem Eng Biotechnol; 2012. E-pub ISSN 1616-8542.

Download references

Acknowledgments

We like to thank the nursing staff at the Centre for Allogeneic Stem Cell Transplantation. The study was supported by grants from The Children’s Cancer Foundation (09/014), Swedish Medical Society, SSMF, Stockholm county Council and Karolinska Institutet.

Conflict of interest

None of the authors have any financial interests to declare.

Author information

Authors and Affiliations

  1. Department of Therapeutic Immunology, Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Huddinge, SE-141 86, Stockholm, Sweden

    Mats Remberger & Olle Ringdén

Authors
  1. Mats Remberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olle Ringdén
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mats Remberger.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 53 kb)

About this article

Cite this article

Remberger, M., Ringdén, O. Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients. Int J Hematol 96, 822–824 (2012). https://doi.org/10.1007/s12185-012-1218-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-012-1218-3

Keywords

Search

Navigation